Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic acid and anthracycline-based chemotherapy

Journal of Clinical Oncology

Volumn 28, Issue 24, 2010, Pages 3872-3879

  Montesinos, Pau ^a   González, José D ^a   González, José ^a   Rayón, Chelo ^a   De Lisa, Elena ^a   Amigo, Maria L ^a   Ossenkoppele, Gert J ^a   Peñarrubia, María J ^a   Pérez Encinas, Manuel ^a   Bergua, Juan ^a   Debén, Guillermo ^a   Sayas, María J ^a   De La Serna, Javier ^a   Ribera, Josep M ^a   Bueno, Javier ^a   Milone, Gustavo ^a   Rivas, Concha ^a   Brunet, Salut ^a   Löwenberg, Bob ^a   Sanz, Miguel ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; RETINOIC ACID; ANTHRACYCLINE; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CHROMOSOME 11Q; CHROMOSOME DELETION 5; CHROMOSOME DELETION 7; CHROMOSOME REARRANGEMENT; DRUG WITHDRAWAL; FEMALE; HIGH RISK PATIENT; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; RECURRENCE RISK; BONE MARROW CANCER; CHEMICALLY INDUCED DISORDER; INCIDENCE; MIDDLE AGED; PROSPECTIVE STUDY; RISK FACTOR; SECOND CANCER; TREATMENT OUTCOME;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW NEOPLASMS; FEMALE; HUMANS; INCIDENCE; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; TRETINOIN;

EID: 77956249684     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.2268     Document Type: Article

References (33)

1. Arana-Yi C, Block AW, Sait SN, et al: Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: Possible role of cytarabine. Leuk Res 32:1043-1048, 2008
2. Latagliata R, Petti MC, Fenu S, et al: Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: An emerging problem. Blood 99:822-824, 2002 (Pubitemid 34525541)
3. Lobe I, Rigal-Huguet F, Vekhoff A, et al: Myelodysplastic syndrome after acute promyelocytic leukaemia: The European APL group experience. Leukemia 17:1600-1604, 2003 (Pubitemid 36986963)
4. Sanz MA, Martín G, González M, et al: Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: A multicenter study by the PETHEMA group. Blood 103:1237-1243, 2004 (Pubitemid 38168633)
5. Sanz MA, Montesinos P, Rayon C, et al: Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: Further improvements in treatment outcome. Blood 115:5137-5146, 2010
6. Sanz MA, Lo Coco F, Martín G, et al: Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups. Blood 96:1247-1253, 2000 (Pubitemid 30658450)
7. Jaffe ES, Harris NL, Stein H, et al: World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, 2001
8. Bolufer P, Barragán E, Sánz MA, et al: Preliminary experience in external quality control of RTPCR PML-RAR alpha detection in promyelocytic leukemia. Leukemia 12:2024-2028, 1998 (Pubitemid 28554475)
9. Bolufer P, Lo Coco F, Grimwade D, et al: Variability in the levels of PML-RAR alpha fusion transcripts detected by the laboratories participating in an external quality control program using several reverse transcription polymerase chain reaction protocols. Haematologica 86:570-576, 2001 (Pubitemid 32601100)
10. Mitelman F (ed): ISCN. Guidelines for Cancer Cytogenetics. Supplement to An International System for Human Cytogenetic Nomenclature. Basel, Switzerland, S. Karger, 1995
11. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21:4642-4649, 2003 (Pubitemid 46594039)
12. Cervera J, Montesinos P, Hernández-Rivas JM, et al: Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica 95:424-431, 2010
13. Kaplan EL, Meier P: Nonparametric estimations from incomplete observations. J Am Stat Assoc 53:457-481, 1958
14. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
15. Gray RJ: A class of K-sample test for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
16. Pepe MS, Mori M: Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med 12:737-751, 1993
17. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B 34:187-220, 1972
18. Dixon WJ: BMDP Statistical Software. Berkeley, CA, University of California Press, 1990
19. Breems DA, Van Putten WL, De Greef GE, et al: Monosomal karyotype in acute myeloid leukemia: A better indicator of poor prognosis than a complex karyotype. J Clin Oncol 26:4791-4797, 2008
20. Weinblatt ME, Fraser P: Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis Rheum 32:1592-1596, 1989 (Pubitemid 20035079)
21. Gutierrez-Ureña S, Molina JF, Garcia CO, et al: Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 39:272-276, 1996 (Pubitemid 26065267)
22. Garcia-Manero G, Kantarjian HM, Kornblau S, et al: Therapy-related myelodysplastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic leukemia (APL). Leukemia 16:1888, 2002
23. Panizo C, Patiño A, Lecumberri R, et al: Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia: Clinical and genetic features of two cases. Cancer Genet Cytogenet 143:178-181, 2003 (Pubitemid 36629328)
24. Athanasiadou A, Saloum R, Zorbas I, et al: Therapy-related myelodysplastic syndrome with monosomy 5 and 7 following successful therapy for acute promyelocytic leukemia with anthracyclines. Leuk Lymphoma 43:2409-2411, 2002 (Pubitemid 35386166)
25. Au WY, Lam CC, Ma ES, et al: Therapy-related myelodysplastic syndrome after eradication of acute promyelocytic leukemia: Cytogenetic and molecular features. Hum Pathol 32:126-129, 2001 (Pubitemid 32150639)
26. Zompi S, Legrand O, Bouscary D, et al: Therapy-related acute myeloid leukaemia after successful therapy for acute promyelocytic leukaemia with t(15;17): A report of two cases and a review of the literature. Br J Haematol 110:610-613, 2000
27. Pedersen-Bjergaard J, Pedersen M, Roulston D, et al: Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 86:3542-3552, 1995
28. Vardiman JW, Thiele J, Arber DA, et al: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 114:937-951, 2009
29. Swerdlow SH, Campo E, Harris NL, et al: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, IARC Press, 2008
30. Chen W, Wang E, Lu Y, et al: Therapy-related acute lymphoblastic leukemia without 11q23 abnormality: Report of six cases and a literature review. Am J Clin Pathol 133:75-82, 2010
31. Andersen MK, Christiansen DH, Jensen BA, et al: Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: Report on two new cases and review of the literature since 1992. Br J Haematol 114:539-543, 2001
32. Grimwade D, Walker H, Oliver F, et al: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial - The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92:2322-2333, 1998 (Pubitemid 28452973)
33. Schmiegelow K, Al-Modhwahi I, Andersen MK, et al: Methotrexate/6- mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: Results from the NOPHO ALL-92 study. Blood 113:6077-6084, 2009